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Abstract: 
Glycogen phosphorylase (GP) appears as a key enzyme for the control of hyperglycaemia in the context of type 2 diabetes. In order to gain 
additional data for structure-activity studies of the inhibition of this enzyme, a series of eight GP inhibitor candidates were prepared from 
peracetylglucopyranosyl azide 1 by click-chemistry. The need for a N-Boc-protected propargylamine was identified in the CuAAC with azide 1 
under Meldal’s conditions, while Sharpless’ conditions were better adapted to the CuAAC of azide 1 with propargyl bromide.  Cycloaddition of 
Boc-propargylamine with azide 1 afforded the N-Boc precursor of a 4-aminomethyl-1-glucosyl-1,2,3-triazole which gave access to a series of 
eight amide and sulfonamide derivatives. After deacetylation, enzymatic studies revealed poor to moderate inhibitions towards this enzyme. 
The N-Boc-protected amine was the best inhibitor (IC50 = 620 µM) unexpectedly slightly better than the 2-naphthylamido substituted analogue 
(IC50 = 650 µM). 
Keywords: Carbohydrate, Triazole, Click chemistry, Inhibitor, Glycogen phophorylase 
1. Introduction 
Glycogen phosphorylase1,2 (GP) is an enzyme responsible for the depolymerization of glycogen and a contributor to hepatic glucose 
output to the blood stream. Hyperglycaemia can be linked to the activity of this enzyme and the tight control of GP activity appears as a 
promising strategy in the context of type 2 diabetes.3-6 Glucose-based derivatives have been intensively studied and provided the most 
populated family of GP inhibitors.7-11 While the best candidates displaying sub-micromolar activities for inhibition of the enzyme are 
spiro-anomeric-bicyclic carbohydrates,12-19 a large set of heteroaromatic glucosides have also been investigated providing inhibitions in 
the low micromolar range.20-28 
N-Acyl-β-D-glucopyranosylamines29 (Figure 1, A) have been reported as good inhibitors of rabbit muscle glycogen phosphorylase b 
(RMGPb), the unphosphorylated isoenzyme typically used for inhibition studies. The bioisosterism between the amide bond and the 
1,2,3-triazole30,31 moiety prompted the synthesis of 1-glucopyranosyl-4-aryl-1,2,3-triazoles32,33 (Figure 1, B). The inhibition of both 
derivatives was in the micromolar range while in the case of N-acyl-N’-β-D-glucopyranosyl ureas with an additional amide bond 
(Figure 1, C) the inhibition was largely improved to reach sub-micromolar Ki values.34 
We therefore decided to synthesize analogues of such triazoles B or ureas C identified as potent GP inhibitors. The corresponding 
analogues (Figure 1, D) can be constructed on a 1,2,3-triazole scaffold displaying a methylamino substituent for amidation with acyl or 
sulfonyl halides. Such molecular design provides a 1,2,3-triazole moiety as a surrogate of the first amide bond while the second amide 
bond is maintained. The methylene group between the triazole and amide functionalities can be seen as a flexible pivotal linkage 
providing a conformational mobility to the scaffold in order to better fit the binding pocket of the enzyme. 
The substituents attached at the amine functionality were chosen in connection with the properties of the so-called β-channel.1 This 
pocket is in close vicinity to the catalytic site of GP and capable of hydrophobic interactions with the heteroaromatic moieties attached 
at the β-anomeric position of the glucose residue. Amide bond were therefore generated with hydrophobic derivatives such as t-
butyloxycarbamate (Boc), acetyl, and phenyl substituents but also with tyrosine, tosyl and hydrophilic phosphonate moieties. 
——— 
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Figure 1. Structural analogy between amide- and triazole-containing GP inhibitors (Ki values are given against RMGPb) 
2. Results and discussion 
2.1. Synthesis 
The synthesis of the target glucose-based inhibitors of GP was performed by 1,3-dipolar cycloaddition of a propargylamine 
derivative with peracetylglucopyranosyl azide 1 (Scheme 1). The development of Cu(I)-catalyzed azide-alkyne cycloaddition35 
(CuAAC) reactions in organic chemistry was boosted after the discovery of reliable and powerful catalysis with Cu(I) species by 
Meldal36 and Sharpless37 following the pioneering discovery on such 1,3-dipolar cycloadditions by Huisgen.38 Although this reaction is 
now intensively used, its outcome sometimes differs from the typical result expected, leading to 5-halogenated 1,2,3-triazoles or even 
5,5’-bis-triazoles under certain conditions.39,27 
In various investigations,40-44 propargylamine has been used as a dipolarophile affording in good to excellent yields 4-aminomethyl-
triazoles of interest. Attempted cycloaddition performed with propargylamine and the azido derivative 1 did not afford cleanly the 
expected triazole but instead a complex mixture containing partially deacetylated compounds most probably through aminolysis of the 
acetate protecting groups in 1 by propargylamine. Even though reacetylation of the crude mixture could be envisaged for the recovery 
of the target compound, this strategy was not further investigated. Fortunately, carbamoylation of propargylamine as the t-
butyloxycarbamate (Boc) derivative allowed for a clean and high yielding (95%) cycloaddition with azide 1 to afford the desired Boc-
protected amine 245 (Scheme 1). This compound was deacetylated under Zemplén conditions to afford compound 3 as a GP inhibitor 
candidate. 
The Boc-protected amine 2 was converted quantitatively by acidic cleavage to the free amine 4 suitable for further functionalization 
with acyl chlorides (Scheme 1, R2COCl) affording the acetylated amides 5a-d which were deprotected to the GP inhibitors candidates 
6a-d. The amine 4 was also converted to the sulfonamide derivative 7 using p-toluenesulfonyl chloride TsCl and subsequent 
deacetylation afforded derivative 8. The sulfonamide 8 was synthesized in order to take advantage of hydrophobic contact in the β-
channel of GP and also to have potential additional contacts with the sulfonamide group and the side chain amino acids of the enzyme. 
Finally, the Boc-protected tyrosine amino acid was conjugated to amine 4 under standard conditions to afford the desired amide 9. The 
phenol moiety of tyrosine did not require a protecting group and was compatible with the amide bond formation. Subsequent one-pot 
deprotection of the carbamate then acetate protecting groups afforded derivative 10. 
 
Scheme 1. a) HC≡CCH2NHBoc, CuI, iPrNEt2, DMF, 70°C, 4 h; b) MeONa, MeOH, rt, 16 h; c) CH2Cl2/TFA (10:1), rt, 4 h; d) R2COCl, Et3N, CH2Cl2, rt, 4 
h; e) TsCl, Et3N, CH2Cl2, rt, 4 h; f) BocTyrOH, EDCI, HOBt, CH2Cl2/DMF (2:1), –10°C, 2 h then rt, 16 h; g) HC≡CCH2Br, CuSO4, sodium ascorbate, 
tBuOH/H2O (1:1), rt, 16 h; h) P(OEt)3, 140°C (µW), 1 h. 
  
 
In order to expand our family/library of triazole-based analogues, the reaction of propargyl bromide with the azido derivative 1 was 
investigated.42 When performed under Meldal’s conditions (CuI, iPrNEt2), a complex reaction mixture was obtained probably due to the 
decomposition of propargyl bromide and also decomposition of the desired cycloadduct. Application of Sharpless’ conditions (CuSO4, 
sodium ascorbate) afforded the desired 4-bromomethyl-1,2,3-triazole 11 in excellent yield (85%). Deacetylation with sodium methoxide 
in methanol (Zemplén conditions) led to a complex mixture of decomposed and partially deprotected compounds probably due to the 
substitution of the bromide atom in the presence of sodium methoxide. Therefore, we did not investigate further this approach but 
decided to take advantage of the bromomethyl group to synthesize a phosphonate analogue. Arbuzov reaction of the brominated 
derivative 11 with triethylphosphite under microwaves activation allowed for the rapid formation of the acetylated phosphonate 12 
which was subsequently converted to phosphonate 13 as a GP inhibitor candidate. Although the preparation of the phosphonate 12 was 
quite simple and high yielding, only one example has been reported in the literature using a different synthetic strategy for a similar 
phosphonate on a triazole scaffold.46 
To summarize, the need for a Boc-protected propargylamine was identified in the CuAAC with azide 1 under Meldal’s conditions, 
while Sharpless’ conditions were better adapted to the CuAAC with propargyl bromide. The CuAAC route from azide 1 led in few steps 
to a series of eight GP inhibitor candidates evaluated to gain additional data for structure-activity studies of the inhibition of this 
enzyme. 
2.2. Enzymatic studies 
The eight inhibitor candidates have been assayed in vitro10 for their inhibitory properties towards RMGPb (Table 1), the model 
enzyme used for the study of GP due to its high similarity (97%) to human isoforms and with complete conservation (100%) at the 
catalytic site.2 
Although compound 2 was just an intermediate in the synthetic route to the target compounds, its Boc-protected derivative 3 was 
considered as a GP inhibitor candidate. Indeed, compared to the other compounds tested (Table 1), an unexpected but significant 
inhibition (IC50 = 620 µM) was observed for the Boc-amine derivative 3, even though it remained below the expected levels (Figure 1). 
The high hydrophobicity of the t-butyl substituent present in the Boc-protected amine is most probably responsible for hydrophobic 
interactions in the β-channel of the enzyme’s catalytic site. 
The 4-amidomethyl-1-glucosylated 1,2,3-triazoles 6a-d displayed IC50 values in the high micromolar range. The acetyl group of 
compound 6a is most probably too small to fit and interact with the amino acids in the β-channel thus providing only 40% inhibition at 
5 mM. As they displayed an aromatic group, compounds 6b and 6c showed improved inhibitory properties although with IC50 values in 
the mM range. As observed for several glucose-based GP inhibitors,10 the best aromatic pharmacophore was almost consistently the 2-
naphthyl moiety and compound 6d displayed the best IC50 value (650 µM) in the 4-amidomethyl-1,2,3-triazole series. 
Besides the replacement of the carbonyl (-CO-) with a sulfonyl group (-SO2-), the sulfonamide 8 differs from the benzamide 6b with 
the presence of a methyl substituent on the phenyl ring. The poor inhibition (30%) observed at 5 mM highlights the negative effect of 
the sulfamide moiety (maybe due to unfavorable structural constraints) and possibly the negative influence of the methyl group. 
Attachment of amino acids to amine intermediate 4 might create additional and positive interactions between the chosen amino acid 
and the enzyme’s catalytic site. Since aromatic groups are usually the best pharmacophores, tyrosine appeared a suitable choice but no 
inhibition was observed at 5 mM for compound 10. The amino acid probably does not fit into the catalytic site of GP probably due to 
size, structure or properties. 
Finally, phosphonate 13 did not display any inhibition at a maximum concentration of 5 mM. 
Table 1. Enzyme kinetic studies of the eight inhibitor candidates (IC50) against RMGPb  
Inhibitor IC50 (µM) 
3 620 
6a 40% inhibition at 5 000a 
6b 1 400 
6c 2 100 
6d 650 
8 30% inhibition at 5 000a 
10 no inhibition at 5 000a 
13 no inhibition at 5 000a 
a
 Percentage of inhibition observed at 5 mM. 
The evaluation of eight GP inhibitor candidates highlighted that the structural design was limited to only a small series of 4-
amidomethyl-1-glucosyl-1,2,3-triazoles while several other structural moieties (sulfamido, amino acid or phosphonate) proved 
detrimental. To our surprise, the inhibitory properties of the Boc-amine protected intermediate 3 were the best in this study although 
with an IC50 value in the high µM range. 
  
Although the present study reveals a novel series of potential GP inhibitors, the poor to moderate inhibition measured did not prompt 
for the detailed study of their interactions at the catalytic site of the enzyme through soaking experiments with the crystallized enzyme. 
The presence of these inhibitors at the catalytic site of the enzyme cannot be proved but only assumed in similarity to almost all 
glucose-based GP inhibitors identified so far.10 Similarly, docking experiments and calculations for the interpretation of the possible 
modes of binding in the catalytic site of the enzyme could be performed but only with more active inhibitors. In silico studies are now 
in progress in order to identify pharmacophores providing a better inhibition. The synthesis and biological evaluation of such GP 
inhibitor candidates will then be performed. 
3. Conclusion 
Cycloaddition of Boc-propargylamine with peracetylated glucosyl azide afforded the precursor of a 4-aminomethyl-1-glucosyl-1,2,3-
triazole which was converted into various amido derivatives. The eight potential GP inhibitors obtained revealed by enzymatic studies 
poor to moderate inhibitions towards this enzyme. The best inhibitor displayed an IC50 value of 620 µM and was actually a Boc-
protected amine derivative which performed almost equally to the 2-naphthylamido substituted inhibitor (IC50 = 650 µM). 
4. Experimental Section 
General methods. All reagents were obtained from commercial sources and used without further purification. Dichloromethane was 
distilled over CaH2 and methanol over Mg/I2. All reactions were performed under an argon atmosphere. Thin-layer chromatography 
(TLC) was carried out on aluminum sheets coated with silica gel 60 F254 (Merck). TLC plates were inspected by UV light (λ = 254 nm) 
and developed by treatment with a mixture of 10% H2SO4 in EtOH/H2O (1:1 v/v) followed by heating. Silica gel column 
chromatography was performed with silica gel Si 60 (40–63 µm). NMR spectra were recorded at 293 K using a Bruker 400 MHz 
spectrometer. Chemical shifts are referenced relative to deuterated solvent residual peaks. The following abbreviations are used to 
explain the observed multiplicities: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet and bs, broad singlet. Complete signal 
assignments were based on 1D and 2D NMR (COSY, HSQC and HMBC correlations). High resolution (HR-ESI-QToF) mass spectra 
were recorded using a Bruker MicroToF-Q II XL spectrometer. Optical rotation was measured using a Perkin Elmer polarimeter at 
20°C and values are given in 10-1 deg.cm2.g-1. 
General procedure A for the coupling of amine 4 with acyl and tosyl chlorides. To a solution of amine 4 (100 mg, 0.23 mmol, 1 
eq.) in anhydrous CH2Cl2 (5 mL) was added Et3N (0.5 mL) and acyl or tosyl chloride (0.46 mmol, 2 eq.). The mixture was stirred at r.t. 
for 4 h, concentrated in vacuo and purified over silica gel chromatography (PE/EtOAc 3:7) to afford products 5a-d and 7. 
General procedure B for the Zemplén deacetylation. To a suspension of acetylated compound (1 eq.) in dry MeOH (5 mL/0.2 
mmol), was added MeONa (0.4 eq.). If the acetylated compound was not soluble in MeOH, CH2Cl2 was added in order to reach 
reasonable solubility. The mixture was stirred at r.t. for 16 h, neutralized with Amberlite IR 120 resin, filtrated and concentrated in 
vacuo to afford the corresponding O-unprotected compounds in quantitative yields. 
tert-Butyl {[1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}carbamate (2)45 
To a suspension of azide 1 (3.99 g, 10.70 mmol, 1 eq.), tert-butyl prop-2-yn-1-ylcarbamate (1.99 g, 12.84 mmol, 1.2 eq.) and CuI 
(0.408 g, 2.14 mmol, 0.2 eq.) in anhydrous DMF (50 mL) was added DIPEA (13.26 mL, 80.25 mmol, 7.5 eq.). The mixture was stirred 
at 70°C for 4 h, cooled down to r.t. and concentrated in vacuo. The crude product was purified over silica gel chromatography 
(CH2Cl2/EtOAc 9:1 then 8:2) to afford 2 as a white powder (5.364 g, 95%). 
mp = 199-200°C (CH2Cl2/PE); Rf = 0.34 (CH2Cl2/EtOAc 8:2); [α]D20 = – 21 (c 1, CHCl3); 1H NMR (CD3OD, 300 MHz) δ 7.79 (br 
s, 1H, H-5’), 5.86 (d, 1H, J = 8.3 Hz, H-1), 5.37-5.46 (m, 2H, H-2, H-3), 5.23 (pdd, 1H, J = 9.7 Hz, H-4), 5.10 (br s, 1H, NH), 4.28 (dd, 
1H, J = 12.6, 4.9 Hz, H-6a), 4.13 (dd, 1H, J = 12.6, 1.9 Hz, H-6b), 3.99 (ddd, 1H, J = 10.0, 4.8, 2.0 Hz, H-5), 2.07, 2.06, 2.0, 1.86 (4s, 
12H, acetyl), 1.44 (s, 9H, tBu); HRMS [ESI+] m/z [M+H]+ calcd for C22H32N4NaO11 551.1960; found 551.1948 
tert-Butyl {[1-(β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}carbamate (3) 
Prepared according to general procedure B. White foam; Rf = 0.18 (EtOAc/MeOH 8:2); [α]D20 = + 2 (c 0.5, MeOH); 1H NMR 
(CD3OD, 400 MHz) δ 8.04 (s, 1H, H-5’), 5.60 (d, 1H, J = 9.1 Hz, H-1), 4.33 (s, 2H, CH2NH), 3.86-3.92 (m, 2H, H-2, H-6a), 3.72 (dd, 
1H, J = 12.2, 5.2 Hz, H-6b), 3.57-3.60 (m, 2H, H-3, H-5), 3.51 (pdd, 1H, J = 9.0 Hz, H-4), 1.44 (s, 9H, tBu); 13C NMR (CD3OD, 100 
MHz) δ 158.3 (C=O), 147.2 (C-4’), 123.2 (C-5’), 89.5 (C-1), 81.0 (C-5), 80.5 (C, tBu), 78.4 (C-3), 74.0 (C-2), 70.8 (C-4), 62.3 (C-6), 
36.6 (CH2NH), 28.7 (CH3, tBu); HRMS [ESI+] m/z [M+Na]+ calcd for C20H22N4NaO6 437.1432; found 434.1430 
[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methanamine (4) 
To a solution of 2 (5.00 g, 9.47 mmol, 1 eq.) in anhydrous CH2Cl2 (50 mL) was added TFA (5 mL). The reaction was stirred at r.t. 
for 4 h and concentrated in vacuo. The crude product was purified over silica gel chromatography (CH2Cl2/MeOH/Et3N 79:20:1) to 
afford 4 as a white foam in a quantitative yield. 
Rf = 0.31 (EtOAc/MeOH 8:2); [α]D20 = – 12 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.69 (s, 1H, H-5’), 5.86 (d, 1H, J = 8.8 Hz, 
H-1), 5.37-5.44 (m, 2H, H-2, H-3), 5.21 (pdd, 1H, J = 9.6 Hz, H-4), 4.27 (dd, 1H, J = 12.6, 4.9 Hz, H-6a), 4.11 (dd, 1H, J = 12.6, 1.8 
Hz, H-6b), 3.99 (ddd, 1H, J = 10.1, 4.8, 1.9 Hz, H-5), 3.96 (br s, 2H, CH2NH2), 2.05, 2.04, 2.00, 1.85 (4s, 12H, acetyl); 13C NMR 
(CDCl3, 100 MHz) δ 170.8, 170.0, 169.5, 169.1 (4C, C=O), 150.3 (C-4’), 119.2 (C-5’), 85.7 (C-1), 75.1 (C-5), 72.7 (C-3), 70.4 (C-2), 
67.8 (C-4), 61.6 (C-6), 37.8 (CH2NH2), 20.8, 20.6, 20.6, 20.3 (4CH3, acetyl); HRMS [ESI+] m/z [M+H]+ calcd for 
C17H25N4O9 429.1616; found 429.1599 
 
 
  
N-{[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}acetamide (5a) 
Prepared according to general procedure A. White powder (101 mg, 92%); mp = 200-201°C (CH2Cl2/PE); Rf = 0.12 
(EtOAc/PE/EtOAc 8:2); [α]D20 = – 14 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.81 (s, 1H, H-5’), 6.40 (br s, 1H, NH), 5.85 (d, 1H, 
J = 9.1 Hz, H-1), 5.38-5.45 (m, 2H, H-2, H-3), 5.24 (pdd, 1H, J = 9.8 Hz, H-4), 4.55 (dd, 1H, J = 15.3, 4.9 Hz, CH2NH), 4.47 (dd, 1H, J 
= 15.3, 4.6 Hz, CH2NH), 4.29 (dd, 1H, J = 12.7, 4.8 Hz, H-6a), 4.14 (dd, 1H, J = 12.6, 1.9 Hz, H-6b), 4.00 (ddd, 1H, J = 10.1, 4.8, 2.0 
Hz, H-5), 2.08, 2.06, 2.02, 2.01 1.87 (5s, 15H, acetyl); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.4, 170.1, 169.5, 169.0 (5C, C=O), 
145.4 (C-4’), 121.1 (C-5’), 86.0 (C-1), 75.3 (C-5), 72.7 (C-3), 70.5 (C-2), 67.7 (C-4), 61.6 (C-6), 35.0 (CH2NH), 23.2, 20.8, 20.7, 20.6, 
20.3 (5CH3, acetyl); HRMS [ESI+] m/z [M+Na]+ calcd for C19H26N4NaO10 493.1541; found 493.1523 
N-{[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}benzamide (5b) 
Prepared according to general procedure A. White powder (109 mg, 89%); mp = 189-190°C (CH2Cl2/PE); Rf = 0.32 (PE/EtOAc 
3:7); [α]D20 = – 27 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.89 (s, 1H, H-5’), 7.78-7.80 (m, 2H, H-Ar), 7.47-7.51 (m, 1H, H-Ar), 
7.40-7.43 (m, 2H, H-Ar), 6.96 (br s, 1H, NH), 5.86 (d, 1H, J = 8.7 Hz, H-1), 5.39-5.47 (m, 2H, H-2, H-3), 5.24 (pdd, 1H, J = 9.6 Hz, H-
4), 4.76 (dd, 1H, J = 15.2, 5.4 Hz, CH2NH), 4.69 (dd, 1H, J = 15.1, 5.3 Hz, CH2NH), 4.29 (dd, 1H, J = 12.6, 4.8 Hz, H-6a), 4.14 (dd, 
1H, J = 12.6, 1.8 Hz, H-6b), 4.00 (ddd, 1H, J = 10.1, 4.8, 2.0 Hz, H-5), 2.06, 2.05, 2.02, 1.85 (4s, 12H, acetyl); 13C NMR (CDCl3, 100 
MHz) δ 170.7, 170.1, 169.5, 169.0, 167.6 (5C, C=O), 145.5 (C-4’), 134.1 (134.1 C-Ar), 131.8 (CH-Ar), 128.7 (2CH-Ar), 127.2 (2CH-
Ar), 121.3 (C-5’), 85.9 (C-1), 75.3 (C-5), 72.8 (C-3), 70.5 (C-2), 67.7 (C-4), 61.6 (C-6), 35.5 (CH2NH), 20.8, 20.7, 20.7, 20.3 (4CH3, 
acetyl); HRMS [ESI+] m/z [M+Na]+ calcd for C24H28N4NaO10 555.1698; found 555.1676 
N-{[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}cinnamamide (5c) 
Prepared according to general procedure A. White powder (122 mg, 95%); mp = 172-173°C (CH2Cl2/PE); Rf = 0.23 (PE/EtOAc 
3:7); [α]D20 = – 16 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.85 (s, 1H, H-5’), 7.64 (d, 1H, J = 15.6 Hz, Csp2H), 7.48-7.50 (m, 2H, 
H-Ar), 7.3-7.37 (m, 3H, H-Ar), 6.51 (br s, 1H, NH), 6.44 (d, 1H, J = 15.6 Hz, Csp2H), 5.86 (d, 1H, J = 8.8 Hz, H-1), 5.39-5.47 (m, 2H, 
H-2, H-3), 5.24 (pdd, 1H, J = 9.6 Hz, H-4), 4.71 (dd, 1H, J = 15.4, 5.8 Hz, CH2NH), 4.62 (dd, 1H, J = 15.4, 5.4 Hz, CH2NH), 4.29 (dd, 
1H, J = 12.6, 4.9 Hz, H-6a), 4.14 (dd, 1H, J = 12.6, 1.9 Hz, H-6b), 4.00 (ddd, 1H, J = 10.1, 4.8, 2.0 Hz, H-5), 2.07, 2.06, 2.02, 1.87 (4s, 
12H, acetyl); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.1, 169.5, 169.0 (5C, C=O), 145.5 (C-4’), 141.6 (Csp2), 134.8 (C-Ar), 130.0 
(CH-Ar), 129.0 (2CH-Ar), 128.0 (2CH-Ar), 121.1 (C-5’), 120.3 (Csp2), 85.9 (C-1), 75.3 (C-5), 72.3 (C-3), 70.5 (C-2), 67.7 (C-4), 61.6 
(C-6), 35.2 (CH2NH), 20.8, 20.7, 20.7, 20.3 (4CH3, acetyl); HRMS [ESI+] m/z [M+Na]+ calcd for C26H30N4NaO10 581.1854; found 
581.1843 
N-{[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}-2-naphthamide (5d) 
Prepared according to general procedure A. White powder (123 mg, 92%); mp = 108-109°C (CH2Cl2/PE); Rf = 0.13 (EtOAc/PE 
4:6); [α]D20 = – 27 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ (s, 1H, H-Ar), 7.97 (s, 1H, H-5’), 7.80-7.87 (m, 4H, H-Ar), 7.47-7.55 
(m, 2H, H-Ar), 7.36 (t, 1H, J = 5.3 Hz, NH), 5.88 (d, 1H, J = 8.9 Hz, H-1), 5.47 (pdd, 1H, J = 9.3 Hz, H-2), 5.42 (pdd, 1H, J = 9.2 Hz, 
H-3), 5.25 (pdd, 1H, J = 9.6 Hz, H-4), 4.82 (dd, 1H, J = 15.2, 5.8 Hz, CH2NH), 4.74 (dd, 1H, J = 15.2, 5.5 Hz, CH2NH), 4.28 (dd, 1H, J 
= 12.6, 4.8 Hz, H-6a), 4.13 (dd, 1H, J = 12.6, 1.9 Hz, H-6b), 4.00 (ddd, 1H, J = 10.1, 4.8, 2.0 Hz, H-5), 2.05, 2.04, 2.01, 1.83 (4s, 12H, 
acetyl); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.1, 169.5, 168.9 (5C, C=O), 145.6 (C-4’), 134.9 (C-Ar), 132.7 (C-Ar), 131.2 (C-Ar), 
129.1 (CH-Ar), 128.5 (CH-Ar), 127.8 (2CH-Ar), 127.8 (CH-Ar), 126.8 (CH-Ar), 123.7 (CH-Ar), 121.5 (C-5’), 85.9 (C-1), 75.2 (C-5), 
72.7 (C-3), 70.5 (C-2), 67.7 (C-4), 61.6 (C-6), 35.5 (CH2NH), 20.8, 20.7, 20.6, 20.3 (4CH3, acetyl); HRMS [ESI+] m/z [M+Na]+ calcd 
for C28H30N4NaO10 605.1854; found 605.1845 
N-{[1-(β-D-Glucopyranosyl)-1,2,3-triazol-4-yl]methyl}acetamide (6a) 
Prepared according to general procedure B. Colorless oil; Rf = 0.14 (CH2Cl2/MeOH 8:2); [α]D20 = + 1 (c 1, MeOH); 1H NMR 
(CD3OD, 400 MHz) δ 8.55 (br s, 1H, NH), 8.07 (s, 1H, H-5’), 5.58 (d, 1H, J = 9.2 Hz, H-1), 4.44 (s, 2H, CH2NH), 3.85-3.90 (m, 2H, H-
2, H-6a), 3.70 (dd, 1H, J = 12.2, 5.4 Hz, H-6b), 3.54-3.63 (m, 2H, H-3, H-5), 3.49 (pdd, 1H, J = 9.2 Hz, H-4), 1.97 (s, 3H, CH3); 13C 
NMR (CD3OD, 100 MHz) δ 173.3 (C=O), 146.3 (C-4’), 123.5 (C-5’), 89.6 (C-1), 81.1 (C-5), 78.4 (C-3), 74.0 (C-2), 70.9 (C-4), 62.4 
(C-6), 35.6 (CH2NH), 22.5 (CH3); HRMS [ESI+] m/z [M+Na]+ calcd for C11H18N4NaO6 325.1119; found 325.1113 
N-{[1-(β-D-Glucopyranosyl)-1,2,3-triazol-4-yl]methyl}benzamide (6b) 
Prepared  according to general procedure B. Colorless oil; Rf = 0.19 (EtOAc/MeOH 8:2); [α]D20 = + 4 (c 1, MeOH); 1H NMR 
(CD3OD, 400 MHz) δ 8.13 (s, 1H, H-5’), 7.85 (d, 2H, J = 7.8 Hz, H-Ar), 7.54 (t, 1H, J = 7.3 Hz, H-Ar), 7.46 (t, 2H, J = 7.5 Hz, H-Ar), 
5.60 (d, 1H, J = 9.2 Hz, H-1), 4.66 (s, 2H, CH2NH), 3.85-3.91 (m, 2H, H-2, H-6a), 3.70 (dd, 1H, J = 12.6, 5.6 Hz, H-6b), 3.55-3.59 (m, 
2H, H-3, H-5), 3.49 (pdd, 1H, J = 9.1 Hz, H-4); 13C NMR (CD3OD, 100 MHz) δ 170.1 (C=O), 146.5 (C-4’), 135.2 (C-Ar), 132.9 (CH-
Ar), 129.6 (2CH-Ar), 128.4 (2CH-Ar), 123.6 (C-5’), 89.6 (C-1), 81.1 (C-5), 78.4 (C-3), 74.0 (C-2), 70.9 (C-4), 62.3 (C-6), 36.1 
(CH2NH); HRMS [ESI+] m/z [M+Na]+ calcd for C16H20N4O6 387.1275; found 387.1277 
N-{[1-(β-D-Glucopyranosyl)-1,2,3-triazol-4-yl]methyl}cinnamamide (6c) 
Prepared according to general procedure B. White foam; Rf = 0.13 (CH2Cl2/MeOH 85:15); [α]D20 = + 7 (c 1, MeOH); 1H NMR 
(CD3OD, 400 MHz) δ 8.13 (s, 1H, H-5’), 7.57 (d, 1H, J = 15.7 Hz, Csp2-H), 7.53-7.55 (m, 2H, H-Ar), 7.35-7.40 (m, 3H, H-Ar), 6.64 (d, 
1H, J = 15.8 Hz, Csp2-H), 5.62 (d, 1H, J = 9.2 Hz, H-1), 4.58 (s, 2H, NH), 3.86-3.94 (m, 2H, H-2, H-6a), 3.72 (dd, 1H, J = 12.1, 5.1 
Hz, H-6b), 3.58-3.62 (m, 2H, H-3, H-5), 3.52 (pdd, 1H, J = 9.0 Hz, H-4); 13C NMR (CD3OD, 100 MHz) δ 168.5 (CONH), 146.2 (C-
4’), 142.2 (Csp2), 136.1 (C-Ar), 130.1 (CH-Ar), 129.9 (2CH-Ar), 128.9 (2CH-Ar), 123.6 (C-5’), 121.4 (Csp2), 89.5 (C-1), 81.0 (C-5), 
78.4 (C-3), 74.0 (C-2), 70.8 (C-4), 62.3 (C-6), 35.7 (CH2NH); HRMS [ESI+] m/z [M+Na]+ calcd for C18H22N4NaO6 413.1436; found 
413.1429 
  
N-{[1-(β-D-Glucopyranosyl)-1,2,3-triazol-4-yl]methyl}naphthamide (6d) 
Prepared according to general procedure B. Colorless oil; Rf = 0.21 (EtOAc/MeOH 8:2); [α]D20 = + 1 (c 1, MeOH); 1H NMR 
(CD3OD, 400 MHz) δ 8.55 (s, 1H, NH), 8.41 (s, 1H, H-Ar), 8.16 (s, 1H, H-5’), 7.90-7.98 (m, 4H, H-Ar), 7.54-7.61 (m, 2H, H-Ar), 5.60 
(d, 1H, J = 9.2 Hz, H-1), 4.72 (s, 2H, CH2NH), 3.90 (pdd, 1H, J = 9.1 Hz, H-2), 3.86 (dd, 1H, J = 12.2, 1.9 Hz, H-6a), 3.70 (dd, 1H, J = 
12.2, 5.4 Hz, H-6b), 3.56 (pdd, 1H, J = 8.8 Hz, H-3), 3.54-3.58 (m, 1H, H-5), 3.49 (pdd, 1H, J = 9.2 Hz, H-4); 13C NMR (CD3OD, 100 
MHz) δ 170.2 (C=O), 146.6 (C-4’), 136.4 (C-Ar), 134.0 (C-Ar), 132.5 (C-Ar), 130.1 (CH-Ar), 129.4 (CH-Ar), 129.0 (CH-Ar), 128.9 
(CH-Ar), 128.8 (CH-Ar), 127.9 (CH-Ar), 124.9 (CH-Ar), 123.7 (C-5’), 89.6 (C-1), 81.1 (C-5), 78.5 (C-3), 74.0 (C-2), 70.9 (C-4), 62.4 
(C-6), 36.2 (CH2NH); HRMS [ESI+] m/z [M+Na]+ calcd for C20H22N4NaO6 437.1432; found 434.1430 
N-{[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}-p-toluenesulfonamide (7) 
Prepared according to general procedure A. White powder (126 mg, 94%); mp = 205-206°C (CH2Cl2/PE); Rf = 0.35 (PE/EtOAc 
4:6); [α]D20 = – 19 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.73-7.75 (m, 3H, H-5’, H-Ar), 7.30 (d, 2H, J = 8.0 Hz, H-Ar), 5.85 (d, 
1H, J = 8.6 Hz, H-1), 5.48 (br s, 1H, NH), 5.36-5.44 (m, 2H, H-2, H-3), 5.23 (pdd, 1H, J = 9.5 Hz, H-4), 4.28 (dd, 1H, J = 12.7, 4.8 Hz, 
H-6a), 4.22 (s, 2H, CH2NH), 4.15 (dd, 1H, J = 12.5, 1.2 Hz, H-6b), 4.01 (ddd, 1H, J = 10.1 4.8, 1.2 Hz, H-5), 2.42 (s, 3H, CH3), 2.06, 
2.05, 2.01, 1.82 (4s, 12H, acetyl); 13C NMR (CDCl3, 100 MHz) δ 170.7, 170.1, 169.5, 169.0 (4C, C=O), 144.7 (C-4’), 143.8 (C-Ar), 
136.5 (C-Ar), 129.9 (2CH-Ar), 127.3 (2CH-Ar), 121.2 (C-5’), 85.8 (C-1), 75.1 (C-5), 72.7 (C-3), 70.5 (C-2), 67.7 (C-4), 61.6 (C-6), 
38.7 (CH2NH), 21.6 (CH3), 20.8, 20.6, 20.6, 20.2 (4CH3, acetyl); HRMS [ESI+] m/z [M+H]+ calcd for C24H31N4O11S 583.1705 ; found 
583.1695 
N-{[1-(β-D-Glucopyranosyl)-1,2,3-triazol-4-yl]methyl}-p-toluenesulfonamide (8) 
Prepared  according to general procedure B. White foam; Rf = 0.21 (CH2Cl2/MeOH 85:15); [α]D20 = + 3 (c 1, MeOH); 1H NMR 
(CD3OD, 400 MHz) δ 7.95 (s, 1H, H-5’), 7.74 (d, 2H, J = 8.2 Hz, H-Ar), 7.38 (d, 2H, J = 8.2 Hz, H-Ar), 5.56 (d, 1H, J = 9.2 Hz, H-1), 
4.15 (s, 2H, CH2NH), 3.88 (dd, 1H, J = 12.2, 1.5 Hz, H-6a), 3.83 (pdd, 1H, J = 9.2 Hz, H-2), 3.72 (dd, 1H, J = 12.2, 5.3 Hz, H-6b), 
3.54-3.62 (m, 2H, H-3, H-5), 3.49 (pdd, 1H, J = 9.2 Hz, H-4), 2.43 (s, 3H, CH3); 13C NMR (CD3OD, 100 MHz) δ 145.7 (C-4’), 144.9 
(C-Ar), 138.5 (C-Ar), 130.9 (2CH-Ar), 128.1 (2CH-Ar), 123.8 (C-5’), 89.5 (C-1), 81.0 (C-5), 78.4 (C-3), 74.0 (C-2), 70.8 (C-4), 62.3 
(C-6), 39.1 (CH2NH), 21.5 (CH3); HRMS [ESI+] m/z [M+H]+ calcd for C16H23N4O7S 415.1286; found 415.1290 
N-{[1-(2,3,4,6-Tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}-N-(tert-butoxycarbonyl)-L-tyrosinamide (9) 
To a solution of Boc-Tyrosine (394 mg, 1.40 mmol, 3 eq) in a 1:1 mixture of anhydrous DMF and CH2Cl2 (10 mL) at –10°C under 
Ar was added HOBt (254 mg, 1.88 mmol, 4 eq.) and EDCI (360 mg, 1.88 mmol, 4 eq.). The mixture was stirred at –10°C for 40 min. 
and then a solution of amine 4 (200 mg, 0.47 mmol, 1 eq.) in anhydrous CH2Cl2 (10 mL) was added dropwise over 60 min. using a 
syringe pump. The mixture was then allowed to warm up to r.t., stirred for an additional 16 h and concentrated in vacuo. The crude 
material was diluted with EtOAc (50 mL), washed with aqueous solutions of HCl 1N (2×20 mL), saturated NaHCO3 (2×20 mL), H2O 
(2×20 mL) and brine (2×20 mL). The organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude product was 
purified over silica gel chromatography (PE/EtOAc 3:7) to afford 9 as a white foam (276 mg, 85%). 
Rf = 0.39 (EtOAc/PE 8:2); [α]D20 = – 41 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.54 (s, 1H, H-5’), 6.92 (d, 2H, J = 7.8 Hz, H-
Ar), 6.69 (d, 2H, J = 8.2 Hz, H-Ar), 5.88 (d, 1H, J = 9.0 Hz, H-1), 5.48 (pdd, 1H, J = 9.3 Hz, H-2), 5.42 (pdd, 1H, J = 9.3 Hz, H-3), 
5.31 (pdd, 1H, J = 9.6 Hz, H-4), 5.23 (d, 1H, J = 7.3 Hz, CHNH), 4.43 (br s, 2H, CH2NH), 4.33 (dd, 1H, J = 12.6, 4.9 Hz, H-6a), 4.17 
(dd, 1H, J = 12.6, 1.9 Hz, H-6b), 4.05 (ddd, 1H, J = 9.9, 4.8, 2.0 Hz, H-5), 3.04 (dd, 1H, J = 13.6, 5.2 Hz, CH2Ph), 2.86 (dd, 1H, J = 
13.6, 7.9 Hz, CH2Ph), 2.07, 2.06, 2.03, 1.85 (4s, 12H, acetyl), 1.41 (s, 9H, tBu); 13C NMR (CDCl3, 100 MHz) δ 171.7 (CONH), 170.9, 
170.2, 169.6, 169.2 (4C, acetyl), 155.5 (CO2tBu), 155.3 (C-Ar), 145.3 (C-4’), 130.6 (2CH-Ar), 128.0 (C-Ar), 121.3 (C-5’), 115.7 (2CH-
Ar), 85.8 (C-1), 80.4 (C, tBu), 75.2 (C-5), 72.9 (C-3), 70.4 (C-2), 67.8 (C-4), 61.8 (C-6), 56.1 (CHNH), 38.0 (CH2Ph) 34.8 (CH2NH), 
28.4 (3CH3, tBu), 20.8, 20.7, 20.7, 20.3 (4CH3, acetyl); HRMS [ESI+] m/z [M+H]+ calcd for C31H42N5O13 692.2774; found 692.2769 
N-{[1-(β-D-Glucopyranosyl)-1,2,3-triazol-4-yl]methyl}-L-tyrosinamide (10) 
To a solution of 9 (60 mg, 0.10 mmol, 1 eq.) in anhydrous CH2Cl2 (10 mL) was added TFA (1 mL). The mixture was stirred at r.t. 
for 4 h and concentrated in vacuo. The product was then suspended in anhydrous MeOH (10 mL) and MeONa (2.2 mg, 0.04 mmol, 0.4 
eq.) was added. The mixture was stirred at r.t. for 16 h and concentrated in vacuo. The crude product was purified by C18 reverse phase 
silica gel chromatography (H2O/MeOH 10:0 then 1:1) to afford 10 as a white foam. 
[α]D20 = + 11 (c 1, MeOH); 1H NMR (CD3OD, 400 MHz) δ 7.70 (s, 1H, H-5’), 6.99 (d, 2H, J = 8.5 Hz, H-Ar), 6.71 (d, 2H, J = 8.5 
Hz, H-Ar), 5.55 (d, 1H, J = 9.2 Hz, H-1), 4.45 (d, 1H, J = 15.4 Hz, CHNH), 4.37 (d, 1H, J = 15.4 Hz, CHNH), 3.88-3.92 (m, 2H, H-2, 
H-6a), 3.73 (dd, 1H, J = 12.1, 5.3 Hz, H-6b), 3.51-3.61 (m, 4H, H-3, H-4, H-5, CHNH2), 2.87 (dd, 1H, J = 13.4, 7.1 Hz, CH2-Ph), 2.79 
(dd, 1H, J = 13.5, 6.7 Hz, CH2-Ph); 13C NMR (CD3OD, 100 MHz) δ 176.3 (CONH), 157.3 (C-Ar), 146.1 (C-4’), 131.5 (2CH-Ar), 
129.1 (C-Ar), 123.5 (C-5’), 116.4 (2CH-Ar), 89.5 (C-1), 81.1 (C-5), 78.5 (C-3), 73.9 (C-2), 70.9 (C-4), 62.4 (C-6), 57.8 (CHNH2), 41.3 
(CH2-Ph), 35.5 (CH2NH); HRMS [ESI+] m/z [M+Na]+ calcd for C18H25N5O7 423.1755; found 423.1750 
4-Bromomethyl-1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazole (11) 
A mixture of azide 1 (2.00 g, 5.36 mmol, 1 eq.), propargyl bromide (0.924 mL, 10.72 mmol, 2 eq.), CuSO4•H2O (267 mg, 1.07 
mmol, 0.2 eq.) and sodium ascorbate (2.123 g, 10.72 mmol, 2 eq.) in tBuOH/H2O (20 mL, 1:1) was stirred at r.t. for 16 h and 
concentrated in vacuo. The crude mixture was filtered through Celite and washed with EtOAc. The solid was discarded and the filtrate 
was concentrated in vacuo and purified over silica gel chromatography (PE/EtOAc 6:4) to afford 11 as a white powder (2.243 g, 85%). 
mp = 153-154°C (CH2Cl2/PE); Rf = 0.52 (PE/EtOAc 1:1); [α]D20 = – 22 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.82 (s, 1H, H-
5’), 5.86 (d, 1H, J = 9.2 Hz, H-1), 5.40-5.43 (m, 2H, H-2, H-3), 5.23 (pdd, 1H, J = 9.8 Hz, H-4), 4.55 (s, 2H, CH2Br), 4.30 (dd, 1H, J = 
  
12.7, 5.0 Hz, H-6a), 4.14 (dd, 1H, J = 12.6, 2.0 Hz, H-6b), 4.00 (ddd,1H, J = 10.1, 5.0, 2.0 Hz, H-5), 2.08, 2.06, 2.0, 1.88 (4s, 12H, 
acetyl); 13C NMR (CDCl3, 100 MHz) δ 170.6, 70.0, 169.5, 169.1 (4C, C=O), 145.5 (C-4’), 121.3 (C-5’), 85.9 (C-1), 75.4 (C-5), 72.6 
(C-3), 70.4 (C-2), 67.8 (C-4), 61.6 (C-6), 21.1 (CH2Br), 20.8, 20.7, 20.7, 20.3 (4CH3, acetyl); HRMS [ESI+] m/z [M+Na]+ calcd for 
C17H22BrN3NaO9 514.0437; found 514.0432 
Diethyl {[1-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}phosphonate (12) 
A solution of 11 (100 mg, 0.20 mmol, 1 eq.) in triethylphosphite (5 mL) was heated at 140°C under microwave conditions for 60 
min, allowed to cool down to r.t. and concentrated in vacuo. The crude mixture was purified over silica gel chromatography (PE/EtOAc 
1:1 then 3:7) to afford 12 as a white powder (96 mg, 86%). 
mp = 132-133°C (CH2Cl2/PE); Rf = 0.09 (EtOAc/PE 113); [α]D20 = – 18 (c 1, CHCl3); 1H NMR (CDCl3, 400 MHz) δ 7.81 (d, 1H, J 
= 2.2 Hz, H-5’), 5.83 (d, 1H, J = 9.0 Hz, H-1), 5.37-5.45 (m, 2H, H-2, H-3), 5.23 (pdd, 1H, J = 9.7 Hz, H-4), 4.29 (dd, 1H, J = 12.6, 4.9 
Hz, H-6a), 4.04-4.15 (m, 5H, H-6b, CH2CH3), 3.98 (ddd, 1H, J = 10.1, 4.8, 2.0 Hz, H-5), 3.31 (d, 2H, J = 20.5 Hz, CH2P), 2.08, 2.05, 
2.02, 1.86 (4s, 12H, acetyl), 1.30 (t, 3H, J = 6.3 Hz, CH2CH3), 1.26 (t, 3H, J = 6.3 Hz, CH2CH3); 13C NMR (CDCl3, 100 MHz) δ 170.7, 
170.1, 169.5, 168.9 (4C, C=O), 139.5 (d, J = 6.8 Hz, C-4’), 121.2 (d, J = 4.2 Hz, C-5’), 85.9 (C-1), 75.2 (C-5), 72.8 (C-3), 70.4 (C-2), 
67.7 (C-4), 62.6 (d, J = 3.4 Hz, CH2CH3), 62.5 (d, J = 3.3 Hz, CH2CH3), 61.6 (C-6), 24.3 (d, J = 142.9 Hz, CH2P), 20.8, 20.7, 20.7, 20.2 
(4CH3, acetyl), 16.5 (d, J = 5.8 Hz, CH2CH3), 16.4 (d, J = 5.9 Hz, CH2CH3); HRMS [ESI+] m/z [M+Na]+ calcd for 
C21H32N3NaO12P 572.1616; found 572.1601 
Diethyl {[1-(β-D-glucopyranosyl)-1,2,3-triazol-4-yl]methyl}phosphonate (13) 
Prepared according to general procedure B. White powder; mp = 132-133°C (MeOH/CH2Cl2); Rf = 0.25 (EtOAc/MeOH 8:2); [α]D20 
= + 4 (c 1, MeOH); 1H NMR (CD3OD, 400 MHz) δ 8.10 (d, 1H, J = 2.6 Hz, H-5’), 5.60 (d, 1H, J = 9.2 Hz, H-1), 4.07-4.15 (m, 4H, 
CH2CH3), 3.86-3.91 (m, 2H, H-2, H-6a), 3.72 (dd, 1H, J = 12.2, 5.4 Hz, H-6b), 3.48-3.60 (m, 3H, H-3, H-4, H-5), 3.40 (d, 2H, J = 20.6 
Hz, CH2P), 1.31 (m, 6H, CH2CH3); 13C NMR (CD3OD, 100 MHz) δ 139.3 (d, J = 8.2 Hz, C-4’), 124.2 (d, J = 5.2 Hz, C-5’), 89.6 (C-1), 
81.1 (C-5), 78.4 (C-3), 74.0 (C-2), 70.9 (C-4), 64.1 (d, J = 3.8 Hz, CH2CH3), 64.0 (d, J = 3.8 Hz, CH2CH3), 62.4 (C-6), 24.1 (d, J = 
143.0 Hz, CH2P), 16.7 (d, J = 6.0 Hz, 2×CH2CH3); HRMS [ESI+] m/z [M+Na]+ calcd for C13H25N3O8P 382.1374; found 382.1367 
Glycogen phosphorylase inhibition measurements (IC50 values). Glycogen phosphorylase b was prepared from rabbit skeletal 
muscle according to the method of Fischer and Krebs,47 using dithiothreitol instead of L-cysteine, and recrystallized at least three times 
before use with a specific activity of 55 U/mg protein. Kinetic experiments were performed in the direction of glycogen synthesis as 
described previously.14 Kinetic data for the inhibition of rabbit skeletal muscle glycogen phosphorylase were collected using different 
concentrations of α-D-glucose-1-phosphate (2–20 mM), constant concentrations of glycogen (1% w/v) and AMP (1 mM), and various 
concentrations of inhibitor. Inhibitor was dissolved in dimethyl sulfoxide (DMSO) and diluted in the assay buffer (50 mM 
triethanolammine, 1 mM EDTA and 1 mM dithiothreitol) so that the DMSO concentration in the assay should be lower than 1%. The 
enzymatic activities were presented in the form of double-reciprocal plots (Lineweaver-Burk) applying a nonlinear data analysis 
program. The means of standard errors for all calculated kinetic parameters averaged to less than 10%. IC50 values were determined in 
the presence of 4 mM α-D-glucose-1-phosphate, 1 mM AMP, 1% glycogen, and varying concentrations of the inhibitor. 
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Supplementary data (1H and 13C NMR for all new compounds) associated with this article can be found, in the online version, at 
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Highlights 
 
1) Glycogen phosphorylase is a target enzyme for the regulation of glycaemia in the context of type 2 
diabetes. 
2) Synthesis of 4-amidomethyl-1-glucosyl-1,2,3-triazoles was achieved from the condensation of glucosyl 
azide and Boc-protected propargyl amine. 
3) Inhibition of GP was in the high micromolar range for the designed inhibitors. 
4) The Boc-carbamate group could be identified as a potential pharmacophore for the inhibition of GP. 
 
